These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32406112)

  • 1. Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
    Rao SSC; Xiang X; Yan Y; Rattanakovit K; Patcharatrakul T; Parr R; Ayyala D; Sharma A
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1332-1341. PubMed ID: 32406112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.
    Lacy BE; Lembo AJ; Macdougall JE; Shiff SJ; Kurtz CB; Currie MG; Johnston JM
    Neurogastroenterol Motil; 2014 Mar; 26(3):326-33. PubMed ID: 24382134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P; Stanghellini V
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System.
    Chang L; Lacy BE; Moshiree B; Kassebaum A; Abel JL; Hanlon J; Bartolini W; Boinpally R; Bochenek W; Fox SM; Mallick M; Tripp K; Omniewski N; Shea E; Borgstein N
    Am J Gastroenterol; 2021 Sep; 116(9):1929-1937. PubMed ID: 34465695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
    Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
    Peng LH; Fang JY; Dai N; Shen XZ; Yang YL; Sun J; Yang YS
    J Dig Dis; 2022 Feb; 23(2):99-110. PubMed ID: 35019221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
    McCormack PL
    Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
    Love BL; Johnson A; Smith LS
    Am J Health Syst Pharm; 2014 Jul; 71(13):1081-91. PubMed ID: 24939497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.